2017
Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
Costa DLC, Diniz JB, Requena G, Joaquim MA, Pittenger C, Bloch MH, Miguel EC, Shavitt RG. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder. The Journal Of Clinical Psychiatry 2017, 78: e766-e773. PMID: 28617566, DOI: 10.4088/jcp.16m11101.Peer-Reviewed Original ResearchMeSH KeywordsAcetylcysteineAdolescentAdultAgedAnxiety DisordersComorbidityDepressive DisorderDouble-Blind MethodDrug ResistanceDrug Therapy, CombinationFemaleHumansMaleMiddle AgedObsessive-Compulsive DisorderPsychiatric Status Rating ScalesPsychometricsSelective Serotonin Reuptake InhibitorsYoung AdultConceptsTreatment-resistant obsessive-compulsive disorderObsessive-compulsive disorderY-BOCS scoresN-acetylcysteineNAC groupYale-Brown Obsessive Compulsive Scale scoresTreatment-resistant OCD patientsBaseline Y-BOCS scoresTreatment-Resistant ObsessivePrimary outcome measureAnxiety symptomsDSM-IV criteriaSymptom dimensionsCompulsive Scale scoresSpecific OCD symptom dimensionsOCD symptom dimensionsAntioxidant medicationsAbdominal painPlacebo groupGlutamate modulatorsSecondary outcomesTertiary hospitalOutpatient clinicSeverity scoreWeek 16
2016
Use of benzodiazepines in obsessive–compulsive disorder
Starcevic V, Berle D, do Rosário M, Brakoulias V, Ferrão Y, Viswasam K, Shavitt R, Miguel E, Fontenelle L. Use of benzodiazepines in obsessive–compulsive disorder. International Clinical Psychopharmacology 2016, 31: 27-33. PMID: 26426443, DOI: 10.1097/yic.0000000000000100.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Anxiety AgentsAnxietyBenzodiazepinesCross-Sectional StudiesDiagnostic and Statistical Manual of Mental DisordersDrug Therapy, CombinationFemaleHumansMaleMiddle AgedObsessive-Compulsive DisorderPsychiatric Status Rating ScalesSelective Serotonin Reuptake InhibitorsSocioeconomic FactorsConceptsObsessive-compulsive disorderBDZ useOCD patientsUse of benzodiazepinesTreatment of OCDBrazilian Research ConsortiumAdditional medicationTreatment guidelinesMulticentre studyReuptake inhibitorsObsessive-compulsive spectrum disordersBenzodiazepine useMarked anxietyPatientsMedicationsBDZDisordersResearch ConsortiumCurrent age
2013
The impact of comorbid body dysmorphic disorder on the response to sequential pharmacological trials for obsessive-compulsive disorder
Diniz J, Costa D, Cassab R, Pereira C, Miguel E, Shavitt R. The impact of comorbid body dysmorphic disorder on the response to sequential pharmacological trials for obsessive-compulsive disorder. Journal Of Psychopharmacology 2013, 28: 603-611. PMID: 24288238, DOI: 10.1177/0269881113512042.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntidepressive Agents, Second-GenerationAntidepressive Agents, TricyclicAntipsychotic AgentsBody Dysmorphic DisordersBrazilClomipramineComorbidityDrug Therapy, CombinationFemaleFluoxetineHumansMaleObsessive-Compulsive DisorderProspective StudiesQuetiapine FumarateRisk FactorsTreatment OutcomeConceptsBody dysmorphic disorderComorbid body dysmorphic disorderPharmacological trialsDysmorphic disorderAdult obsessive-compulsive disorder (OCD) patientsSequential treatment strategyObsessive-compulsive disorder patientsSequential treatmentFluoxetine monotherapyClinical characteristicsObsessive-compulsive disorderInitial severityTreatment strategiesDisorder patientsTreatment groupsPatientsWorse responseBDD patientsEffects of sexGEE modelTrialsDisordersSequential trialsWeeksType of augmentation
2011
A Double-Blind, Randomized, Controlled Trial of Fluoxetine Plus Quetiapine or Clomipramine Versus Fluoxetine Plus Placebo for Obsessive-Compulsive Disorder
Diniz J, Shavitt R, Fossaluza V, Koran L, de Bragança Pereira C, Miguel E. A Double-Blind, Randomized, Controlled Trial of Fluoxetine Plus Quetiapine or Clomipramine Versus Fluoxetine Plus Placebo for Obsessive-Compulsive Disorder. Journal Of Clinical Psychopharmacology 2011, 31: 763-768. PMID: 22020357, DOI: 10.1097/jcp.0b013e3182367aee.Peer-Reviewed Original ResearchConceptsY-BOCS scoresFluoxetine groupTreatment regimenSelective serotonin reuptake inhibitorsPlacebo-controlled trialSevere adverse eventsSerotonin reuptake inhibitorsMain outcome measuresObsessive-compulsive disorder patientsCompulsive Scale scoresYale-Brown ObsessiveFluoxetine monotherapyAdverse eventsReuptake inhibitorsObsessive-compulsive disorderPrimary diagnosisOutcome measuresDisorder patientsScale scoreFluoxetineMental disordersQuetiapinePatientsStatistical ManualClomipramine
2009
Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial
Diniz J, Shavitt R, Pereira C, Hounie A, Pimentel I, Koran L, Dainesi S, Miguel E. Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial. Journal Of Psychopharmacology 2009, 24: 297-307. PMID: 19164490, DOI: 10.1177/0269881108099423.Peer-Reviewed Original ResearchObsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol
R. A, Hounie A, Sampaio A, Arrais J, Miguel E, Elkis H. Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol. Comprehensive Psychiatry 2009, 50: 437-442. PMID: 19683614, DOI: 10.1016/j.comppsych.2008.11.005.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntidepressive AgentsAntipsychotic AgentsClozapineComorbidityDiagnostic and Statistical Manual of Mental DisordersDrug Therapy, CombinationFemaleHaloperidolHumansInterview, PsychologicalMaleMiddle AgedObsessive-Compulsive DisorderPsychiatric Status Rating ScalesPsychometricsSchizophreniaYoung AdultConceptsObsessive-compulsive disorderObsessive-compulsive symptomsSchizophrenia patientsPrevalence of OCDSchizophrenia rating scalesPresence of OCSPrevalence of patientsUse of clozapineUse of antidepressantsClinical Global ImpressionPANSS total scoreCross-sectional studyStructured Clinical InterviewHigher severity scoresNegative Syndrome ScaleHigher severityYale-Brown ObsessiveGlobal ImpressionSeverity scorePatientsClozapineClinical InterviewHaloperidolSchizophrenia symptomsSyndrome Scale
2005
Citalopram plus reboxetine in treatment-resistant obsessive-compulsive disorder
Fontenelle L, Mendlowicz M, Miguel E, Versiani M. Citalopram plus reboxetine in treatment-resistant obsessive-compulsive disorder. The World Journal Of Biological Psychiatry 2005, 6: 57-59. PMID: 16097406, DOI: 10.1080/15622970510029740.Peer-Reviewed Original ResearchConceptsTreatment-resistant obsessive-compulsive disorderObsessive-compulsive disorderSRI-resistant obsessive compulsive disorderResistant obsessive-compulsive disorderCombination of citalopramFirst-line treatmentAdequate trialReuptake inhibitorsCompulsive disorderPatientsCitalopramDisordersFuture studiesTrials